Truncated Pleurocidin Derivative with High Pepsin Hydrolysis Resistance to Combat Multidrug-Resistant Pathogens.

Dejuan Wang, Jingru Shi, Chen Chen, Zhiqiang Wang, Yuan Liu
Author Information
  1. Dejuan Wang: College of Veterinary Medicine, Yangzhou University, Yangzhou 225009, China.
  2. Jingru Shi: College of Veterinary Medicine, Yangzhou University, Yangzhou 225009, China.
  3. Chen Chen: College of Veterinary Medicine, Yangzhou University, Yangzhou 225009, China.
  4. Zhiqiang Wang: College of Veterinary Medicine, Yangzhou University, Yangzhou 225009, China. ORCID
  5. Yuan Liu: College of Veterinary Medicine, Yangzhou University, Yangzhou 225009, China. ORCID

Abstract

The global prevalence of antimicrobial resistance calls for the development of novel antimicrobial agents, particularly for these orally available drugs. Structural modifications of the natural antimicrobial peptides (AMPs) provide a straightforward approach to develop potent antimicrobial agents with high specificity and low toxicity. In this study, we truncated 11-amino-acids at the C-terminus of Pleurocidin, an AMP produced by , and obtained four peptide analogues termed GK-1, GK-2, GK-3 and GK-4. Minimum inhibitory concentration (MIC) tests showed that GK-1 obtained by direct truncation of Pleurocidin has no antibacterial activity, while GK-2, GK-3 and GK-4 show considerable antibacterial activity with Pleurocidin. Notably, GK-4 displays rapid bacteriostatic activity, great stability and low hemolysis, as well as enhanced hydrolytic resistance to pepsin treatment. Mechanistic studies showed that GK-4 induces membrane damage by interacting with bacterial membrane-specific components, dissipates bacterial membrane potential and promotes the generation of ROS. SEM and CD analysis further confirmed the ability of GK-4 to resist pepsin hydrolysis, which may be attributed to its stable helicity structure. Collectively, our findings reveal that GK-4 is a potential orally available candidate to treat infections caused by multidrug-resistant pathogens.

Keywords

References

  1. Acta Biomater. 2016 Jan;30:78-93 [PMID: 26546414]
  2. Pharmaceutics. 2021 Mar 24;13(4): [PMID: 33804947]
  3. PLoS Pathog. 2021 Sep 3;17(9):e1009909 [PMID: 34478485]
  4. Adv Drug Deliv Rev. 2021 Aug;175:113818 [PMID: 34090965]
  5. Biotechnol Adv. 2022 Mar-Apr;55:107901 [PMID: 34974156]
  6. Biochimie. 2010 Sep;92(9):1236-41 [PMID: 20188791]
  7. Proc Natl Acad Sci U S A. 2019 Aug 13;116(33):16529-16534 [PMID: 31358625]
  8. Biomaterials. 2015;53:415-25 [PMID: 25890739]
  9. Int Immunopharmacol. 2022 Jun;107:108699 [PMID: 35305384]
  10. Nat Microbiol. 2017 Dec;2(12):1667-1675 [PMID: 28970486]
  11. Front Immunol. 2021 Nov 19;12:740620 [PMID: 34867962]
  12. Int J Mol Sci. 2021 May 24;22(11): [PMID: 34073939]
  13. Environ Sci Pollut Res Int. 2022 Jul;29(35):52665-52674 [PMID: 35267162]
  14. Eur J Med Chem. 2018 Apr 25;150:546-558 [PMID: 29549839]
  15. J Phys Chem B. 2021 Jul 8;125(26):7163-7176 [PMID: 34171196]
  16. Front Microbiol. 2021 Aug 19;12:708712 [PMID: 34489898]
  17. Trends Biotechnol. 2011 Sep;29(9):464-72 [PMID: 21680034]
  18. Proc Natl Acad Sci U S A. 2019 Dec 16;: [PMID: 31843919]
  19. Nat Rev Microbiol. 2020 Mar;18(3):164-176 [PMID: 31792365]
  20. Eur J Med Chem. 2017 Jan 5;125:551-564 [PMID: 27718471]
  21. Pharmaceuticals (Basel). 2021 Jul 17;14(7): [PMID: 34358113]
  22. Commun Biol. 2020 Nov 27;3(1):697 [PMID: 33247193]
  23. Theranostics. 2020 Jan 1;10(3):1373-1390 [PMID: 31938070]
  24. Int J Mol Sci. 2022 Feb 16;23(4): [PMID: 35216307]
  25. Microorganisms. 2020 Sep 11;8(9): [PMID: 32932906]
  26. Crit Rev Microbiol. 2022 Mar 7;:1-25 [PMID: 35254957]
  27. J Med Chem. 2022 Mar 24;65(6):5085-5094 [PMID: 35290038]
  28. ACS Infect Dis. 2019 Jan 11;5(1):123-130 [PMID: 30372023]
  29. J Med Chem. 2019 Mar 14;62(5):2286-2304 [PMID: 30742437]
  30. Curr Opin Microbiol. 2014 Oct;21:1-6 [PMID: 25078317]
  31. J Med Chem. 2021 Nov 25;64(22):16854-16863 [PMID: 34784220]
  32. Chem Biol. 2013 Sep 19;20(9):1168-78 [PMID: 23972939]
  33. FEMS Microbiol Rev. 2016 Jan;40(1):133-59 [PMID: 25862689]
  34. Biomaterials. 2015 Jun;52:517-30 [PMID: 25818457]
  35. Mar Drugs. 2022 Feb 25;20(3): [PMID: 35323465]
  36. Microbiol Spectr. 2021 Dec 22;9(3):e0131821 [PMID: 34908502]
  37. Biomaterials. 2015 Mar;43:44-9 [PMID: 25591960]
  38. Nat Biomed Eng. 2020 May;4(5):560-571 [PMID: 32393891]
  39. Sci Adv. 2022 Jan 07;8(1):eabk1792 [PMID: 34985942]
  40. Molecules. 2020 Nov 30;25(23): [PMID: 33266085]
  41. Nat Rev Microbiol. 2015 May;13(5):310-7 [PMID: 25817583]
  42. Int J Mol Sci. 2021 May 19;22(10): [PMID: 34069596]
  43. ACS Appl Mater Interfaces. 2021 Apr 14;13(14):16062-16074 [PMID: 33797891]
  44. Small. 2022 Feb;18(5):e2104211 [PMID: 34825488]
  45. Soft Matter. 2021 Jul 21;17(28):6773-6786 [PMID: 34212942]
  46. Front Microbiol. 2021 Oct 08;12:746006 [PMID: 34690992]
  47. Nat Commun. 2017 Nov 8;8(1):1365 [PMID: 29118336]
  48. J Fungi (Basel). 2022 Feb 10;8(2): [PMID: 35205928]
  49. Biomolecules. 2020 Oct 23;10(11): [PMID: 33113998]
  50. Chem Rev. 2017 Jun 28;117(12):8094-8128 [PMID: 28541045]

Grants

  1. 2021YFD1801000 and 2018YFA0903400/National Key Research and Development Program of China
  2. 32222084, 32172907 and 32002331/National Natural Science Foundation of China

Word Cloud

Created with Highcharts 10.0.0GK-4antimicrobialPleurocidinresistanceactivityagentsorallyavailableAMPslowobtainedGK-1GK-2GK-3showedantibacterialpepsinmembranebacterialpotentialglobalprevalencecallsdevelopmentnovelparticularlydrugsStructuralmodificationsnaturalpeptidesprovidestraightforwardapproachdeveloppotenthighspecificitytoxicitystudytruncated11-amino-acidsC-terminusAMPproducedfourpeptideanaloguestermedMinimuminhibitoryconcentrationMICtestsdirecttruncationshowconsiderableNotablydisplaysrapidbacteriostaticgreatstabilityhemolysiswellenhancedhydrolytictreatmentMechanisticstudiesinducesdamageinteractingmembrane-specificcomponentsdissipatespromotesgenerationROSSEMCDanalysisconfirmedabilityresisthydrolysismayattributedstablehelicitystructureCollectivelyfindingsrevealcandidatetreatinfectionscausedmultidrug-resistantpathogensTruncatedDerivativeHighPepsinHydrolysisResistanceCombatMultidrug-ResistantPathogensbacteria

Similar Articles

Cited By